ライフサイエンスコーパス: AMI

1 AMI was the primary diagnosis in 32 695 (49%) of these 6

2 tion: HF, 0.008% (95% CI, 0.007% to 0.010%); AMI, -0.003% (95% CI, -0.005% to -0.001%); and pneumonia

3 267 763 and 276 031 AMI hospitalizations among older and younger patients, r

4 ositive: HF, 0.066 (95% CI, 0.036 to 0.096); AMI, 0.067 (95% CI, 0.027 to 0.106); and pneumonia, 0.10

5 tudy was conducted of patients enrolled in 2 AMI registries: PREMIER, from January 1, 2003, to June 2

6 We studied 9,290 AMI patients treated with PCI and discharged alive betwe

7 Orbitrap) mass spectrometry we identified 33 AMI metabolites (both Phase I and Phase II), occurring m

8 During 5.8 years of follow-up, 490 AMI events (1.9%) occurred.

9 This study evaluated the association of 5 AMI admission therapies (aspirin, beta-blockers, acute r

10 Among 112,668 AMI survivors, 5% had cardiogenic shock during hospitali

11 Among 753 AMI patients in the prognostic cohort, cytochrome c was

12 Overall, 18 369 785 AMI/stroke hospitalizations were included in the analysi

13 crosis factor-alpha, conditions accompanying AMI, reduce the endothelial expression of cGKI and enhan

14 (662 [94.4%] vs 1107 [91.3%]; P = .01) after AMI.

15 ipoprotein-associated phospholipase A2 after AMI compared with men, and this remained statistically s

16 and Measures: Loss of sexual activity after AMI.

17 ith diabetes mellitus discharged alive after AMI from 24 US hospitals and then validated the models i

18 Treatment with ACEI/ARB after AMI was associated with improved long-term survival, reg

19 the regenerative capacity of BM cells after AMI.

20 chanically ventilated patients with CS after AMI, routine treatment with pMCS was not associated with

21 ted from 87 participants 14 to 21 days after AMI and BM from healthy donors was used as a reference.

22 and statins, and survived >/=180 days after AMI hospitalization in 2008 to 2010.

23 eutrophil infiltration/activity 2 days after AMI were attenuated in knockout mice with endothelial GC

24 ts (who survive the first several days after AMI) do not.

25 D2N times and shorter life expectancy after AMI.

26 colony outgrowth and cardiac function after AMI.

27 7 days (early) or 3 to 4 weeks (late) after AMI.

28 women have higher inflammatory levels after AMI compared with young men.

29 men were significantly higher than men after AMI (hazard ratio, 1.29 for women; 95% confidence interv

30 physician about sex in the first month after AMI were more likely to delay resuming sex (adjusted odd

31 phospholipase A2 were measured 1 month after AMI.

32 SAQ domain scores during the 12 months after AMI between patients who did and did not participate in

33 d with poor health status at 12 months after AMI, but this was attenuated after adjustment for patien

34 ith 30-d, 1-y, 5-y, and 17-y mortality after AMI while adjusting for patient comorbidities, frailty m

35 an important risk factor for mortality after AMI, independent of confounding by comorbidities, frailt

36 ide range of risk for adverse outcomes after AMI in diabetic patients.

37 reased risk of cardiovascular outcomes after AMI, but little is known about whether young women have

38 tion in CR with health status outcomes after AMI.

39 te weight gain in underweight patients after AMI are worthy of testing.

40 statins on survival among older people after AMI.

41 ed with 1-year rehospitalization rates after AMI.

42 lop prediction models to stratify risk after AMI in patients with diabetes mellitus.

43 ife expectancy and years of life saved after AMI were calculated using Cox proportional hazards regre

44 ife expectancy and years of life saved after AMI.

45 investigate whether ACEI/ARB treatment after AMI is associated with better outcomes across different

46 ent follow-up beyond the first 6 weeks after AMI is associated with worse short-term and long-term pa

47 Two weeks after AMI, increased PB platelet-derived growth factor BB glyc

48 on of days covered >/=80%) in the year after AMI hospitalization.

49 among young women than men in the year after AMI.

50 of loss of sexual activity in the year after AMI.

51 compared with men over the first year after AMI.

52 hospitalizations within the first year after AMI.

53 pinephrine reuptake inhibitor Amitriptyline (AMI) for treatment of mental health problems has led to

54 tinuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) included in a large Swedish

55 lder than 65 years discharged alive after an AMI between January 2, 2007, and October 1, 2010, from 4

56 for limiting ventricular remodeling after an AMI.

57 .7 years, 212 patients (8.2%) experienced an AMI.

58 function in the mice that had experienced an AMI.

59 d improves ventricular function following an AMI.

60 e 1-hour protocol, 777 (60%) patients had an AMI excluded.

61 ive death (aOR, 0.79; 95% CI, 0.77-0.81) and AMI (aOR, 0.87; 95% CI, 0.84-0.89) but an increase in pe

62 ood-frequency questionnaire (3C Bordeaux and AMI).

63 Despite reductions in the rate of death and AMI among patients undergoing major noncardiac surgery i

64 G and hs-cTnT measurements were obtained and AMI outcomes adjudicated during initial hospitalization.

65 To assess AMI bioconcentration factors, tissue distribution, and m

66 Among patients adherent to statins before AMI hospitalization, 32.6% became nonadherent after disc

67 7 to 2011, taking statins in the year before AMI hospitalization (n=6618).

68 ion of days covered <80%) in the year before AMI hospitalization who became statin adherent (proporti

69 Time-updated VACS Index provided better AMI and mortality prediction than CD4 count and HIV-1 RN

70 es cardiac function in animal models of both AMI and chronic ischemic cardiomyopathy.

71 ial, 48 patients with severe CS complicating AMI were assigned to pMCS (n = 24) or IABP (n = 24).

72 ) in patients with severe shock complicating AMI.

73 There were no deaths, AMIs, or coronary revascularizations in either group.

74 cted AMI and a prognostic cohort of definite AMI patients.

75 eated depression adjusting for demographics, AMI severity, and clinical factors.

76 oprotein cholesterol (LDL) of 130-159 mg/dL, AMI rates were 5.44 (4.97, 5.91) for HCV-positive and 4.

77 n rates were stable across hospitals (except AMI at nonpenalty hospitals).

78 Necrosis and inflammation after experimental AMI were compared between control mice and littermates w

79 Although experimental AMI models have implicated cytokine-related impairment o

80 INTERHEART was a case-control study of first AMI in 52 countries.

81 ive method for quantifying the AAR following AMI, which unlike T2-mapping, is not affected by IPC.

82 novel approach to quantify the AAR following AMI.

83 rted health status during the year following AMI; however, participation in CR did confer a significa

84 2962554 hospitalizations for HF, 1229939 for AMI, and 2544530 for pneumonia were identified at 5016,

85 95% confidence interval {CI}, 1.71-5.38] for AMI and 2.59 [95% CI, 1.97-3.41] for stroke).

86 re 24.6% and 8.4% for HF, 19.3% and 7.6% for AMI, and 18.3% and 8.5% for pneumonia.

87 tal inpatient facilities after admission for AMI (OR, 3.14 [95% CI, 1.72-5.74]) or stroke (OR, 1.45;

88 e during hospitalization after admission for AMI or stroke (odds ratio, 3.03 [95% confidence interval

89 e during hospitalization after admission for AMI or stroke.

90 rocess and identify a proximal biomarker for AMI.

91 ent-years (95% confidence interval [CI]) for AMI among total cholesterol (TC) 200-239 stratum were 5.

92 Sensitivity of the risk classification for AMI ranged from 87.5% to 100% in individual studies.

93 hy evidence of AMI, inpatient ICD-9 code for AMI (410), or AMI as underlying cause of death [Internat

94 ster compared with nontarget conditions (for AMI, additional decline of -0.49 [95% CI, -0.81 to -0.16

95 OD AND A total of 105 patients evaluated for AMI in the emergency departments of 2 teaching hospitals

96 ng nonadherent patients, hospitalization for AMI was associated with increased likelihood of becoming

97 ar mortality rates after hospitalization for AMI were similar across county income groups, decreasing

98 readmission rates after hospitalization for AMI, CHF, or pneumonia for hospitals in the highest-perf

99 readmission rates after hospitalization for AMI, CHF, or pneumonia for hospitals in the highest-perf

100 babilities of death and hospitalizations for AMI and stroke within a 5-year follow-up period were ide

101 Adults hospitalized for AMI from 1 October 2010 to 30 September 2014.

102 Those hospitalized for AMI were less likely to become nonadherent than those ho

103 Patients hospitalized for AMI were more likely to become adherent than patients ho

104 y of Medicare beneficiaries hospitalized for AMI, with 17 years of follow-up.

105 er in VA hospitals than non-VA hospitals for AMI (13.5% vs 13.7%, P = .02; -0.2 percentage-point diff

106 However, rates of PCI for AMI and shock were lower in New York throughout the stud

107 Discriminatory power for AMI, as quantified by the area under the receiver-operat

108 k-standardized all-cause mortality rates for AMI and HF, and higher 30-day risk-standardized all-caus

109 spitalization and 1-year mortality rates for AMI from January 1, 1999, to December 31, 2013, were mea

110 ossover approach to estimate odds ratios for AMI occurring within 1 hour of triggers.

111 dults with MDD have a 30% increased risk for AMI than HIV-infected adults without MDD after adjustmen

112 Guideline-based therapy for AMI admission is associated with both early and late sur

113 d the diagnosis in 1 man was downgraded from AMI to unstable angina.

114 of beta-catenin and Nanog in myocardium from AMI mice.

115 r hs-cTnT<14 ng/L over serial testing or had AMI excluded by the 1-hour protocol.

116 Fourteen (0.5%) low-risk patients had AMI.

117 ents <0.005 microg/L) and the number who had AMI during hospitalization (primary outcome) or a major

118 aged 65 years or older hospitalized with HF, AMI, or pneumonia from January 1, 2008, through December

119 nts in Acute Myocardial Infarction (HORIZONS-AMI) clinical trial was performed between March 1, 2015,

120 with STEMI who were enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Ste

121 The correlation in hospital AMI achievement scores for each age group was also calcu

122 In AMI study participants, the angiogenic cytokine platelet

123 In AMI swine studies, transendocardial stem cell injection

124 Route of delivery was analyzed in AMI swine studies and clinical trials (6 clinical trials

125 The rate of decline in AMI hospitalizations was similar for all county income g

126 One early event in AMI is the increased cardiac expression of atrial natriu

127 inhibits neutrophil-platelet interactions in AMI patients by targeting neutrophils.

128 in modulating the efficacy of MSC therapy in AMI swine studies and clinical trials, suggesting the su

129 We determined incident AMI rates among HCV-positive and HCV-negative men among

130 Main Outcomes and Measures: Incident AMI (defined by discharge summary documentation, enzyme/

131 Primary outcome was incident AMI rates by HCV status in each lipid strata using Natio

132 The primary outcomes were incident AMI (Medicaid, Medicare, and Veterans Affairs Internatio

133 Baseline MDD was associated with incident AMI after adjusting for demographics (hazard ratio [HR],

134 ic disorder was not associated with incident AMI.

135 erson-years) were analyzed with 196 incident AMIs and 1710 deaths.

136 lth Questionnaire-9 (PHQ-9) during the index AMI admission.

137 ospitalized for acute myocardial infarction (AMI) (n = 3665).

138 Risk of acute myocardial infarction (AMI) among hepatitis C virus (HCV)-positive versus HCV-n

139 y patients with acute myocardial infarction (AMI) and cardiogenic shock survive hospitalization; litt

140 MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical stu

141 MSC therapy in acute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical stu

142 f patients with acute myocardial infarction (AMI) and in control plasma of healthy donors in order to

143 V infection and acute myocardial infarction (AMI) and stroke outcomes, we analyzed hospital discharge

144 tes (RSMRs) for acute myocardial infarction (AMI) are calculated for Medicare beneficiaries.

145 o experience an acute myocardial infarction (AMI) are sexually active before the AMI, but little is k

146 t, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high.

147 te diagnosis of acute myocardial infarction (AMI) currently constitutes an unmet need.

148 nT) in a 1-hour acute myocardial infarction (AMI) exclusion algorithm.

149 s with possible acute myocardial infarction (AMI) has been shown to effectively identify a substantia

150 mortality from acute myocardial infarction (AMI) has decreased, whereas the prevalence of AMI has in

151 Treatment of acute myocardial infarction (AMI) has improved significantly in recent years, but man

152 ear cells after acute myocardial infarction (AMI) has led to limited improvement in left ventricular

153 rs of age) with acute myocardial infarction (AMI) have higher mortality risk than similarly aged men.

154 patients after acute myocardial infarction (AMI) improves long-term prognosis, yet the current rates

155 d with incident acute myocardial infarction (AMI) in a large cohort of adults with HIV.

156 in and rule-out acute myocardial infarction (AMI) in the emergency department include a rapid assessm

157 key feature of acute myocardial infarction (AMI) is an alteration in cardiac architecture.

158 g patients with acute myocardial infarction (AMI) is prevalent and associated with an adverse quality

159 infarct size in acute myocardial infarction (AMI) patients.

160 mortality from acute myocardial infarction (AMI) remains significant, and the prevalence of post-myo

161 n therapies for acute myocardial infarction (AMI) significantly improve 30-day survival, but little i

162 of death after acute myocardial infarction (AMI) than normal weight patients; however, it is unclear

163 mended after an acute myocardial infarction (AMI) to reduce ischemic events but is associated with in

164 f patients with acute myocardial infarction (AMI) was carried out with screen-printed electrodes modi

165 For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if beta-b

166 (AAR) following acute myocardial infarction (AMI), and has been used to assess myocardial salvage by

167 t failure (HF), acute myocardial infarction (AMI), and pneumonia.

168 talizations for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and w

169 talizations for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and w

170 eadmissions for acute myocardial infarction (AMI), heart failure (HF), and pneumonia.

171 e hospitals for acute myocardial infarction (AMI), heart failure (HF), or pneumonia using the Medicar

172 ause mortality, acute myocardial infarction (AMI), ischemic stroke (IS), hemorrhagic stroke, and new-

173 ll-cause death, acute myocardial infarction (AMI), or acute ischemic stroke, were evaluated over time

174 oung women with acute myocardial infarction (AMI), who represent an extreme phenotype.

175 e could trigger acute myocardial infarction (AMI).

176 r discharge for acute myocardial infarction (AMI).

177 tients after an acute myocardial infarction (AMI).

178 he diagnosis of acute myocardial infarction (AMI).

179 ly diagnosis of acute myocardial infarction (AMI).

180 ed with risk of acute myocardial infarction (AMI).

181 rted to trigger acute myocardial infarction (AMI).

182 e rapidly after acute myocardial infarction (AMI).

183 commended after acute myocardial infarction (AMI).

184 apidly rule out acute myocardial infarction (AMI).

185 a heart attack (acute myocardial infarction, AMI), there is no biomarker to indicate an impending car

186 1 activity with the CARM1-specific inhibitor AMI-1 significantly increased spine width and mushroom-t

187 A higher proportion of AMI than non-AMI patients had pre-operative intra-aortic balloon pump

188 d of death (HR: 0.57; p = 0.04) than the non-AMI group did.

189 ry end points were all-cause death, nonfatal AMI, rehospitalization for evaluation of possible AMI, a

190 At 1-year post-VAD, 52% of AMI patients were alive with ongoing device support, 25.

191 At 1 month post-VAD, 91.8% of AMI patients were alive with ongoing device support, 7.2

192 nt of adverse remodeling in the aftermath of AMI.

193 Of 12 461 cases of AMI 13.6% (n=1650) engaged in physical activity and 14.4

194 In this analysis, we included only cases of AMI and used a case-crossover approach to estimate odds

195 e to hs-cTnT and hs-cTnI in the diagnosis of AMI and may perform favorably in patients presenting ear

196 The final diagnosis of AMI was independently adjudicated using all available cl

197 en using hs-cTnT levels for the diagnosis of AMI.

198 the uniform cutoff level in the diagnosis of AMI.

199 45 men (18.6%) received a final diagnosis of AMI.

200 alternative to cTn in the early diagnosis of AMI.

201 The relative tissue distribution of AMI was consistent at both doses, with concentrations de

202 tion, enzyme/electrocardiography evidence of AMI, inpatient ICD-9 code for AMI (410), or AMI as under

203 patients with an incident hospitalization of AMI (index date) between 2007 and 2011.

204 Candidate genes indicative of AMI were nominated from microarray of enriched CEC sampl

205 e epidemiology, diagnosis, and management of AMI in young women (when compared with men) across the c

206 using an electronic health record measure of AMI mortality endorsed by the National Quality Forum.

207 period was associated with increased odds of AMI (odds ratio, 2.31; 99% confidence interval [CI], 1.9

208 iod was associated with an increased odds of AMI (odds ratio, 2.44; 99% CI, 2.06-2.89) with a populat

209 iated with a further increase in the odds of AMI (odds ratio, 3.05; 99% CI, 2.29-4.07; P for interact

210 dications, or time of day or day of onset of AMI.

211 MI) has decreased, whereas the prevalence of AMI has increased markedly, particularly among patients

212 A higher proportion of AMI than non-AMI patients had pre-operative intra-aortic

213 993-2008), we determined that proportions of AMI claims decreased in the primary position (from 65% t

214 Hospitalization and mortality rates of AMI declined among counties of all income levels, althou

215 nts undergoing interventional reperfusion of AMI, elective percutaneous or surgical coronary revascul

216 associated with a 3.4-fold increased risk of AMI (adjusted odds ratio [aOR] = 3.41; 95% confidence in

217 ne were associated with an increased risk of AMI among patients carrying the rs2236225 minor A allele

218 HCV-positive men have a higher risk of AMI than HCV-negative men at higher TC/LDL levels; this

219 has not posed a threat of increased risk of AMI, stroke, or all-cause mortality.

220 associated with a further increased risk of AMI.

221 during ARI episodes may increase the risk of AMI.

222 ed to identify a transcriptomic signature of AMI present in whole blood, but derived from CECs.

223 pective piece is to review recent studies of AMI in young women.

224 gency department with symptoms suggestive of AMI, concentrations of cMyC, and high-sensitivity (hs) a

225 Hospital survivors of AMI who had cardiogenic shock have a higher risk of deat

226 AMI, inpatient ICD-9 code for AMI (410), or AMI as underlying cause of death [International Statisti

227 events (MACEs) occurred at 30 days (death or AMI).

228 on of plasma samples to the groups of HDs or AMI patients.

229 ischemic electrocardiogram (ECG) to rule out AMI in adults presenting to the emergency department (ED

230 a nonischemic ECG may successfully rule out AMI in patients presenting to EDs with possible emergenc

231 d assessment 0-/1-hour algorithm to rule-out AMI with high-sensitivity troponin may be insufficient f

232 ire high sensitivity to confidently rule-out AMI, whereas cardiologists aim to minimize false-positiv

233 In the 15-year study period, AMI risk-standardized hospitalization and mortality rate

234 Plasma PLP (AMI patients only) and PA predicted all-cause mortality

235 nts in the emergency department for possible AMI from 2011 to 2013.

236 Among patients evaluated for possible AMI in the emergency department with a modified HEART sc

237 rehospitalization for evaluation of possible AMI, and coronary revascularization at 30 days.

238 Patients with possible AMI can be triaged within 1 hour after admission with no

239 nd cell phenotypes, cell functions, and post-AMI cardiac function were determined.

240 cluding their pre-AMI, in-hospital, and post-AMI periods, and highlight gaps in knowledge and outcome

241 HODS AND We assessed sex differences in post-AMI inflammatory markers and whether such differences ac

242 ual differences in the intensity of the post-AMI inflammatory response, involving 1 or more inflammat

243 s the continuum of care, including their pre-AMI, in-hospital, and post-AMI periods, and highlight ga

244 r risk factors, 6 of the 9 metrics predicted AMI and all metrics predicted mortality.

245 This PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controll

246 evels, diagnostic reclassification regarding AMI occurred in only 3 patients: 0.11% (95% CI, 0.02-0.3

247 increase in diagnostic claims for secondary AMI identifies a unique high-risk population and has imp

248 cohort of patients presenting with suspected AMI and a prognostic cohort of definite AMI patients.

249 cluded 2734 adults presenting with suspected AMI.

250 The AMI group had higher unadjusted early phase hazard (haza

251 oss of sexual activity in the year after the AMI.

252 more incident problems in the year after the AMI.

253 arction (AMI) are sexually active before the AMI, but little is known about sexual activity or sexual

254 accounting for established risk factors, the AMI group no longer had higher early mortality hazard (H

255 ted proliferation of reparative cells in the AMI hearts.

256 r creatinine, not working at the time of the AMI, older age, lower hemoglobin, left ventricular dysfu

257 ely these data indicate that, in addition to AMI, a broad suite of metabolites should be included in

258 2 women was upgraded from unstable angina to AMI, and the diagnosis in 1 man was downgraded from AMI

259 a more targeted, community-based approach to AMI prevention.

260 e exposed gilt-head bream (Sparus aurata) to AMI in seawater for 7 days at two concentrations (0.2 mu

261 if these 2 pathways interact in relation to AMI.

262 The TRAPID-AMI trial study (High-Sensitivity Troponin-T Assay for R

263 struction is abolished in metoprolol-treated AMI patients.

264 aptured 180 days after cART initiation until AMI, death, last clinic visit, or 30 September 2012.

265 Final diagnosis was AMI in 340 patients (17%).

266 lth status, using data from 2219 adults with AMI, 18 to 55 years of age, in the United States.

267 We included patients >/=65 years of age with AMI from the ACTION Registry-GWTG (Acute Coronary Treatm

268 (P=0.52), showed an overall association with AMI.

269 sociations of plasma serine and glycine with AMI.

270 Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospi

271 of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and Jun

272 women) >/=18 years of age hospitalized with AMI from 24 US centers into the TRIUMPH study (Translati

273 Among older men with AMI, HF, or pneumonia, hospitalization at VA hospitals,

274 ll colony maximum in the BM of patients with AMI (estimate+/-SE, -0.13+/-0.05; P=0.007).

275 y is an effective strategy for patients with AMI and acute heart failure or shock in whom medical the

276 Among 45977 patients with AMI and cardiogenic shock (11298 in New York), 21 974 (4

277 molecular signature identifies patients with AMI and sets the framework to potentially identify the e

278 lization databases to identify patients with AMI and shock from January 1, 2002, through December 31,

279 mortality was compared between patients with AMI having: (1) no depression (PHQ-9<10; reference); (2)

280 Of the 57,574 patients with AMI included in this cohort, 5,678 (9.8%) were underweig

281 l mortality rankings for older patients with AMI inconsistently reflect rankings for younger patients

282 her treatment of depression in patients with AMI is associated with better outcomes.

283 Although depression in patients with AMI is associated with increased long-term mortality, th

284 Outcomes for older patients with AMI may not reflect general outcomes.

285 te ischemic preconditioning in patients with AMI reported reduced infarct size, it would be premature

286 discrimination between HDs and patients with AMI was assessed on the basis of electrochemical thresho

287 Patients with AMI who receive VAD have outcomes similar to other VAD p

288 a-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction

289 Of the 9,290 patients with AMI, bleeding events occurred as follows: any BARC bleed

290 Relevance: In a cohort of 4929 patients with AMI, we found that those who did and did not participate

291 nd 0.6% (95% CI, 0.13-1.85) of patients with AMI.

292 Young women presenting with AMI may develop coronary disease by different mechanisms

293 essed by the sensitivity and proportion with AMI ruled out and the positive predictive value and prop

294 l activity and anger or emotional upset with AMI to quantify the importance of these potential trigge

295 Young women with AMI had higher inflammatory levels compared with young m

296 enrolled 4062 patients aged >/=18 years with AMI between April 11, 2005, and December 31, 2008, from

297 rs) and all patients (aged >/=18 years) with AMI.

298 spital death among patients in New York with AMI and shock decreased significantly faster after the p

299 ficantly higher in those with versus without AMI (median, 237 ng/L versus 13 ng/L, P<0.001).

300 ecovery: Role of Gender on Outcomes of Young AMI Patients study (conducted from August 21, 2008, to J